Condition: Advanced Solid Tumor (Phase 1) · Sponsor: Epics Therapeutics
This the first-in-human (FIH) study for the Investigational Medicinal Product (IMP) EP102, is designed to explore the maximum tolerated dose (MTD), the overall safety profile, its pharmacokinetic (PK) / pharmacodynamic (PD) profile, and an exploratory evaluation of antitumor activity in participants with advanced solid tumors, who have no available standard therapy or who have failed standard therapies. This study will inform on recommended doses for further studies, e.g. dose optimization studies and / or efficacy and safety studies.
This description comes directly from the study's public registry record.
Clinical Trial Liaison · +32 71 348 500 · info@epicstx.com
Always discuss trial participation with your own doctor first.
| Institut Jules Bordet | Brussels, Belgium | Recruiting |
| Cliniques universitaires Saint-Luc | Brussels, Belgium | Recruiting |
| Universitair Ziekenhuis Gent (UZ Gent) - Drug Research Unit Gent (DRUG) | Ghent, Belgium | Recruiting |
| Leuven Cancer Institute (LKI) | Leuven, Belgium | Recruiting |
| Masaryk Memorial Cancer Institute | Brno, Czechia | Recruiting |
| Olomouc University Hospital | Olomouc, Czechia | Recruiting |
| Netherlands Cancer Institute (NKI) | Amsterdam, Netherlands | Recruiting |
| University Medical Center Groningen, University of Groningen Department of Medical Oncology | Groningen, Netherlands | Recruiting |
| Hospital Universitari Vall d'Hebron - Vall d'Hebron Institute of Oncology | Barcelona, Spain | Recruiting |
| START Madrid - CIOCC | Madrid, Spain | Recruiting |
| Hospital Universitario de Santiago de Compostela | Santiago de Compostela, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07163325